NuCana (NASDAQ:NCNA) Downgraded by BidaskClub

BidaskClub lowered shares of NuCana (NASDAQ:NCNA) from a sell rating to a strong sell rating in a research note released on Tuesday, BidAskClub reports.

Several other analysts have also recently weighed in on the company. Zacks Investment Research cut Hancock Jaffe Laboratories from a buy rating to a hold rating in a report on Wednesday, June 26th. William Blair reissued an outperform rating on shares of NuCana in a report on Thursday, May 16th. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average target price of $25.50.

NASDAQ:NCNA opened at $9.75 on Tuesday. The firm has a market cap of $317.75 million, a PE ratio of -17.11 and a beta of 3.29. The business’s 50 day moving average price is $11.71. NuCana has a 1-year low of $9.03 and a 1-year high of $30.10.

NuCana (NASDAQ:NCNA) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.22) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.22). Equities analysts forecast that NuCana will post -1.14 EPS for the current year.

A number of institutional investors have recently bought and sold shares of NCNA. Rothschild Investment Corp IL bought a new position in NuCana during the 1st quarter worth $211,000. Asymmetry Capital Management L.P. increased its stake in NuCana by 5.4% during the 1st quarter. Asymmetry Capital Management L.P. now owns 45,393 shares of the company’s stock worth $772,000 after acquiring an additional 2,346 shares during the period. Marshall Wace North America L.P. increased its stake in NuCana by 558.8% during the 1st quarter. Marshall Wace North America L.P. now owns 60,843 shares of the company’s stock worth $1,034,000 after acquiring an additional 51,607 shares during the period. Alps Advisors Inc. increased its stake in NuCana by 5.6% during the 1st quarter. Alps Advisors Inc. now owns 77,838 shares of the company’s stock worth $1,323,000 after acquiring an additional 4,160 shares during the period. Finally, Partner Fund Management L.P. increased its stake in NuCana by 14.9% during the 4th quarter. Partner Fund Management L.P. now owns 447,420 shares of the company’s stock worth $6,488,000 after acquiring an additional 58,062 shares during the period. Hedge funds and other institutional investors own 38.03% of the company’s stock.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer.

See Also: Quiet Period Expirations Explained

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.